ISU Abxis Co Ltd

086890

Company Profile

  • Business description

    ISU Abxis Co Ltd is engaged in developing and manufacturing therapeutic antibodies in South Korea. It offers Abciximab, Clotinab, Abcertin, and Fabagal used to treat incurable diseases such as cancer and rare diseases.

  • Contact

    3Fl. Kookje Bldg
    90-1 Daeshin-dong
    Seodaemun-gu
    Seoul120-160
    KOR

    T: +82 222278888

    http://www.abxis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    185

Stocks News & Analysis

stocks

Major ASX miner reduces aluminium exposure

The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
stocks

Vegemite owner’s shares remain expensive on normalising profits.

Australian dairy staple to see profits normalise with shares screening as overvalued.
stocks

Ask the analyst: Where does GYG stand following its US exit?

All roads lead back home for Guzman Y Gomez.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,037.0011.200.12%
CAC 408,485.8422.23-0.26%
DAX 4025,725.7553.56-0.21%
Dow JONES (US)52,977.9077.830.15%
FTSE 10010,655.7723.26-0.22%
HKSE23,616.32266.291.14%
NASDAQ25,832.67207.36-0.80%
Nikkei 22569,737.696.38-0.01%
NZX 50 Index13,763.10144.681.06%
S&P 5007,509.3726.130.35%
S&P/ASX 2008,831.0012.700.14%
SSE Composite Index4,041.242.41-0.06%

Market Movers